Your browser is no longer supported. Please, upgrade your browser.
Settings
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own0.31% Shs Outstand108.33M Perf Week10.31%
Market Cap579.57M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float105.59M Perf Month-29.61%
Income-136.70M PEG- EPS next Q-0.29 Inst Own- Short Float7.13% Perf Quarter-36.16%
Sales78.90M P/S7.35 EPS this Y7.20% Inst Trans0.08% Short Ratio11.12 Perf Half Y-50.92%
Book/sh-0.28 P/B- EPS next Y71.40% ROA-36.20% Target Price21.33 Perf Year-42.41%
Cash/sh1.73 P/C3.09 EPS next 5Y- ROE- 52W Range4.26 - 13.97 Perf YTD-19.43%
Dividend- P/FCF- EPS past 5Y4.30% ROI-43.00% 52W High-61.70% Beta0.65
Dividend %- Quick Ratio2.80 Sales past 5Y142.00% Gross Margin96.90% 52W Low25.59% ATR0.36
Employees174 Current Ratio2.90 Sales Q/Q-74.30% Oper. Margin- RSI (14)46.29 Volatility3.97% 7.03%
OptionableYes Debt/Eq- EPS Q/Q10.70% Profit Margin- Rel Volume1.00 Prev Close5.12
ShortableYes LT Debt/Eq- EarningsFeb 21 BMO Payout- Avg Volume677.06K Price5.35
Recom2.20 SMA205.25% SMA50-15.15% SMA200-43.53% Volume680,289 Change4.49%
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Apr-26-11Initiated Wedbush Outperform $3
Oct-29-08Downgrade Piper Jaffray Neutral → Sell
Mar-07-08Downgrade Piper Jaffray Buy → Neutral
Oct-31-07Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $5
Aug-07-07Reiterated Punk, Ziegel & Co Buy $24 → $7
Feb-15-19 02:11PM  SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
12:11PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:35AM  Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
Feb-14-19 04:12PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX GlobeNewswire
01:39PM  Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc. PR Newswire
12:00PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) GlobeNewswire
Feb-13-19 11:40AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
08:15AM  New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-12-19 06:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE
Feb-11-19 12:39PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
10:22AM  Here's Why Lexicon Pharmaceuticals Lost 28.8% in January Motley Fool
Feb-08-19 03:31PM  RM LAW Announces Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc. PR Newswire
Feb-07-19 05:36PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  LXRX GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX) & ProShares Short VIX Short-Term Futures ETF (SVXY) GlobeNewswire
Feb-06-19 11:47AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Feb-05-19 11:47AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Feb-04-19 11:45AM  Lawsuit for Investors in Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation ACCESSWIRE
Feb-03-19 09:23AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX ACCESSWIRE
Feb-01-19 11:24AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Jan-31-19 07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline LXRX ACCESSWIRE +7.26%
07:40AM  Research Report Identifies Knight-Swift Transportation, Alteryx, Lexicon Pharmaceuticals, Procter & Gamble, MicroStrategy, and SMART SAND INC with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-30-19 06:07PM  LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm PR Newswire
05:54PM  Robbins Arroyo LLP: Lexicon Pharmaceuticals, Inc. (LXRX) Misled Shareholders According to a Recently Filed Class Action Business Wire
11:24AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 ACCESSWIRE
Jan-29-19 06:14PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc. Business Wire
04:42PM  About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
02:31PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019 GlobeNewswire
10:36AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Lexicon Pharmaceuticals, Inc. GlobeNewswire
12:18AM  Pomerantz Law Firm Announces the Filing of a Class Action against Lexicon Pharmaceuticals, Inc. and Certain Officers  LXRX GlobeNewswire
Jan-24-19 02:06PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX GlobeNewswire -8.78%
Jan-22-19 08:52PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX PR Newswire
12:00PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) GlobeNewswire
Jan-21-19 01:51PM  Does Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Have A High Beta? Simply Wall St.
Jan-18-19 11:53AM  Here's Why Lexicon Pharmaceuticals Collapsed Today Motley Fool -22.60%
07:49AM  The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug Benzinga
Jan-17-19 06:22PM  Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes GlobeNewswire
06:20PM  Lexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee Meeting for Sotagliflozin in Type 1 Diabetes GlobeNewswire
06:20PM  FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults With Type 1 Diabetes GlobeNewswire
07:12AM  Lexicon Pharmaceuticals stock to be halted Thursday as FDA committee reviews diabetes treatment MarketWatch
07:05AM  Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes GlobeNewswire
Jan-07-19 07:05AM  Lexicon Pharmaceuticals has Upcoming FDA Dates, Phase I Results, Analysts Review and Target ACCESSWIRE
Dec-21-18 12:45PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -8.65%
Dec-20-18 07:00AM  Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes GlobeNewswire
Dec-18-18 07:00AM  Lexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211 GlobeNewswire
Dec-11-18 06:00AM  3 Top Biotech Stocks to Buy in December Motley Fool
Nov-29-18 09:00AM  FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes GlobeNewswire
Nov-23-18 09:22AM  Should You Worry About Lexicon Pharmaceuticals Incs (NASDAQ:LXRX) CEO Pay Cheque? Simply Wall St. -7.65%
Nov-12-18 07:20AM  Report: Developing Opportunities within Lexicon Pharmaceuticals, Cray, RCI Hospitality, Sanmina, Diamond Offshore Drilling, and Cerus Future Expectations, Projections Moving into 2018 GlobeNewswire -6.58%
Nov-08-18 04:00PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Nov-06-18 11:25PM  Edited Transcript of LXRX earnings conference call or presentation 1-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Nov-05-18 08:53AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Nov-01-18 09:01AM  Lexicon: 3Q Earnings Snapshot Associated Press +6.26%
07:00AM  Lexicon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides a Business Update GlobeNewswire
Oct-25-18 07:00AM  Lexicon Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 1, 2018 GlobeNewswire +8.57%
Oct-18-18 07:30AM  Investor Expectations to Drive Momentum within Amkor Technology, Lexicon Pharmaceuticals, Parker Drilling, HFF, The Chefs' Warehouse, and Payment Data Discovering Underlying Factors of Influence GlobeNewswire
Oct-16-18 08:00AM  Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of XERMELO® (Telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination With Somatostatin Analog Therapy GlobeNewswire +7.50%
Sep-24-18 07:00AM  Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 54th Annual Meeting GlobeNewswire
07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Aug-30-18 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Aug-28-18 08:25AM  Research Report Identifies Convergys, Amkor Technology, Discovery, Inc., ServiceMaster Global, Acadia Healthcare, and Lexicon Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.11%
Aug-22-18 04:22PM  UPDATE: Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
04:00PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Aug-06-18 01:39PM  Edited Transcript of LXRX earnings conference call or presentation 30-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
Jul-31-18 04:00PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Jul-30-18 08:10AM  Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates Zacks -7.45%
07:00AM  Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update GlobeNewswire
06:00AM  Lexicon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-28-18 02:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Jul-26-18 09:00AM  New Insights Revealed in National Survey Show More Advances Are Needed for the Type 1 Diabetes Community PR Newswire
Jul-23-18 04:46PM  UPDATE - Lexicon Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018 GlobeNewswire
04:01PM  Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018 GlobeNewswire
Jul-16-18 07:05AM  Free Technical Research on Marinus Pharma and Three More Biotech Equities ACCESSWIRE
Jul-02-18 12:27AM  Edited Transcript of LXRX earnings conference call or presentation 3-May-18 12:00pm GMT Thomson Reuters StreetEvents +6.17%
Jul-01-18 05:14PM  Insider Buys Of The Week: AbbVie, Energen, NuStar And More Benzinga
Jun-27-18 11:58AM  Should You Follow This Trend For Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)? Simply Wall St.
07:30AM  Research Report Identifies Citizens Financial Group, Fifth Third, KKR & Co., Vista Outdoor, Devon Energy, and Lexicon Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-25-18 07:45AM  Insider Buys Of The Week: DDR, Salesforce, Lexicon Pharma Benzinga -5.01%
Jun-24-18 04:01PM  Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care GlobeNewswire
Jun-23-18 01:30PM  Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care GlobeNewswire
Jun-18-18 07:00AM  Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions GlobeNewswire
Jun-15-18 07:55AM  Free Technical Reports on MannKind and Three Additional Biotech Equities ACCESSWIRE
Jun-02-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
May-24-18 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-23-18 02:29PM  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx Zacks
May-22-18 08:03AM  FDA to review Zynquista (sotagliflozin) as potential treatment for type 1 diabetes GlobeNewswire
May-11-18 07:40AM  New Research: Key Drivers of Growth for E.W. Scripps, Switch, Realogy, The Charles Schwab, CenterPoint Energy, and Lexicon Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
07:05AM  Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks ACCESSWIRE
May-08-18 07:50AM  Blog Exposure - Lexicon Pharmas New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics ACCESSWIRE
May-04-18 08:00AM  Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical Therapeutics GlobeNewswire +5.42%
May-03-18 07:00AM  Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update GlobeNewswire
May-01-18 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Apr-26-18 07:00AM  Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018 GlobeNewswire
Apr-21-18 07:16AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-03-18 07:00AM  Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018 GlobeNewswire
Apr-02-18 01:16PM  Woodlands pharma co. total revenue 'wont grow a lot' year over year American City Business Journals
Mar-29-18 01:00AM  Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes GlobeNewswire
Mar-28-18 07:10AM  Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes ACCESSWIRE
Mar-26-18 07:36PM  Edited Transcript of LXRX earnings conference call or presentation 22-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Invus Public Equities, L.P.DirectorJun 28Buy12.4557,724718,9353,516,214Jun 29 04:23 PM
Invus Public Equities, L.P.DirectorJun 27Buy12.54125,1141,568,4423,458,490Jun 29 04:23 PM
Invus Public Equities, L.P.DirectorJun 25Buy12.95228,2642,955,0833,333,376Jun 26 05:32 PM
Invus Public Equities, L.P.DirectorJun 22Buy13.3625,461340,0903,105,112Jun 26 05:32 PM
Invus Public Equities, L.P.DirectorJun 21Buy13.2751,600684,6133,079,651Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 20Buy13.2812,391164,6133,028,051Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 19Buy13.458,982120,8193,015,660Jun 21 05:55 PM
Invus Public Equities, L.P.DirectorJun 18Buy13.0636,584477,9373,006,678Jun 18 06:56 PM
Invus Public Equities, L.P.DirectorJun 14Buy12.669,200116,4622,970,094Jun 18 06:56 PM
Invus Public Equities, L.P.DirectorJun 12Buy12.83107,0231,373,2442,960,894Jun 12 06:10 PM
Invus Public Equities, L.P.DirectorJun 11Buy12.7598,6261,257,4522,853,871Jun 12 06:10 PM
Tessmer James FVP, Finance & AccountingJun 08Option Exercise10.1510,000101,50035,643Jun 12 04:37 PM
Invus Public Equities, L.P.DirectorJun 08Buy12.8929,747383,4272,755,245Jun 12 06:10 PM
Tessmer James FVP, Finance & AccountingJun 08Sale12.9110,000129,07625,643Jun 12 04:37 PM
Invus Public Equities, L.P.DirectorJun 07Buy12.9357,439742,5082,725,498Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 06Buy12.5895,0791,196,3702,668,059Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 05Buy12.45173,1212,156,1872,572,980Jun 07 07:37 PM
Invus Public Equities, L.P.DirectorJun 04Buy12.24121,8031,490,5762,399,859Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorJun 01Buy12.22147,3391,800,0412,278,056Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorMay 31Buy11.62147,3391,712,0502,130,717Jun 04 05:31 PM
Invus Public Equities, L.P.DirectorMay 30Buy10.32147,3391,521,0251,983,378May 30 08:53 PM
Invus Public Equities, L.P.DirectorMay 29Buy9.84147,3391,450,4201,836,039May 30 08:53 PM
Invus Public Equities, L.P.DirectorMay 25Buy9.62138,7001,334,9741,688,700May 30 08:53 PM
Santini Alexander AEVP and CCOMay 23Buy9.787457,2865,297May 25 04:43 PM